A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
BO43936
Phase 2 other active
Quick answer
A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma for Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma is a Phase 2 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Phase
- Phase 2
- Modality
- other
- Status
- active